Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist
Controlled trialHumans
- Design
- Controlled trial
- Subjects
- Patients with moderate carpal tunnel syndrome; number not given in the abstract
- Dose used in the study
- PEA 600 mg or 1200 mg a day; untreated control group
- Duration
- 30 days
- What was measured
- Median nerve distal motor latency by electroneurography; Tinel's sign; symptoms
What the authors reported
PEA shortened the prolonged median nerve latency (p < 0.0004), with a larger effect at the higher dose. Tinel's sign and discomfort were also reduced.
Limits of this study
Control group received no treatment, so no placebo and no blinding. Sample size not in the abstract. 30 days. Two authors are affiliated with Epitech, which makes the PEA product used in Italian trials of this era. No DOI.
Source
Entry checked against the abstract, supplied by Devlin. Sample size not in the abstract on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.